Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,655.00
-45.00 (-1.22%)
At close: Apr 20, 2026
Market Cap56.02B -24.8%
Revenue (ttm)201.20B +5.7%
Net Income-605.35M
EPS-40.00
Shares Out15.33M
PE Ration/a
Forward PEn/a
Dividend75.00 (2.13%)
Ex-Dividend DateDec 29, 2025
Volume73,746
Average Volume51,809
Open3,700.00
Previous Close3,700.00
Day's Range3,650.00 - 3,705.00
52-Week Range3,120.00 - 5,760.00
Beta0.46
RSI58.31
Earnings Daten/a

About Korea Arlico Pharm

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. The company provides ETC, OTC, medical device, and other products; and active ingredients. It offers products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. w... [Read more]

Industry Pharmaceutical Preparations
Founded 1992
Employees 112
Stock Exchange KOSDAQ
Ticker Symbol 260660
Full Company Profile

Financial Performance

In 2025, Korea Arlico Pharm's revenue was 201.20 billion, an increase of 5.65% compared to the previous year's 190.44 billion. Losses were -605.35 million, -88.70% less than in 2024.

Financial Statements